Logo image of 1COV.DE

COVESTRO AG (1COV.DE) Stock Fundamental Analysis

Europe - FRA:1COV - DE0006062144 - Common Stock

59.96 EUR
-0.24 (-0.4%)
Last: 10/23/2025, 7:00:00 PM
Fundamental Rating

2

Overall 1COV gets a fundamental rating of 2 out of 10. We evaluated 1COV against 66 industry peers in the Chemicals industry. Both the profitability and financial health of 1COV have multiple concerns. 1COV does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year 1COV has reported negative net income.
In the past year 1COV had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: 1COV reported negative net income in multiple years.
In the past 5 years 1COV always reported a positive cash flow from operatings.
1COV.DE Yearly Net Income VS EBIT VS OCF VS FCF1COV.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B

1.2 Ratios

The Return On Assets of 1COV (-2.86%) is worse than 69.70% of its industry peers.
1COV has a Return On Equity of -6.14%. This is in the lower half of the industry: 1COV underperforms 71.21% of its industry peers.
Industry RankSector Rank
ROA -2.86%
ROE -6.14%
ROIC N/A
ROA(3y)-1.76%
ROA(5y)1.73%
ROE(3y)-3.61%
ROE(5y)3.67%
ROIC(3y)N/A
ROIC(5y)N/A
1COV.DE Yearly ROA, ROE, ROIC1COV.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

1COV's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 14.09%, 1COV is not doing good in the industry: 77.27% of the companies in the same industry are doing better.
1COV's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for 1COV so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 14.09%
OM growth 3Y-78.51%
OM growth 5Y-54.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18%
GM growth 5Y-7.1%
1COV.DE Yearly Profit, Operating, Gross Margins1COV.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

3

2. Health

2.1 Basic Checks

1COV does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 1COV remains at a similar level compared to 1 year ago.
Compared to 5 years ago, 1COV has more shares outstanding
1COV has a better debt/assets ratio than last year.
1COV.DE Yearly Shares Outstanding1COV.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
1COV.DE Yearly Total Debt VS Total Assets1COV.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

2.2 Solvency

An Altman-Z score of 2.35 indicates that 1COV is not a great score, but indicates only limited risk for bankruptcy at the moment.
1COV has a Altman-Z score of 2.35. This is comparable to the rest of the industry: 1COV outperforms 54.55% of its industry peers.
1COV has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of 1COV (0.34) is better than 62.12% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Altman-Z 2.35
ROIC/WACCN/A
WACC6.4%
1COV.DE Yearly LT Debt VS Equity VS FCF1COV.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.3 Liquidity

1COV has a Current Ratio of 1.39. This is a normal value and indicates that 1COV is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.39, 1COV is not doing good in the industry: 68.18% of the companies in the same industry are doing better.
A Quick Ratio of 0.74 indicates that 1COV may have some problems paying its short term obligations.
With a Quick ratio value of 0.74, 1COV is not doing good in the industry: 80.30% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 0.74
1COV.DE Yearly Current Assets VS Current Liabilites1COV.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

3

3. Growth

3.1 Past

The earnings per share for 1COV have decreased strongly by -17.54% in the last year.
1COV shows a decrease in Revenue. In the last year, the revenue decreased by -1.98%.
The Revenue has been growing slightly by 2.70% on average over the past years.
EPS 1Y (TTM)-17.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.42%
Revenue 1Y (TTM)-1.98%
Revenue growth 3Y-3.75%
Revenue growth 5Y2.7%
Sales Q2Q%-8.43%

3.2 Future

The Earnings Per Share is expected to grow by 20.27% on average over the next years. This is a very strong growth
Based on estimates for the next years, 1COV will show a small growth in Revenue. The Revenue will grow by 0.72% on average per year.
EPS Next Y-7.01%
EPS Next 2Y60.31%
EPS Next 3Y48.4%
EPS Next 5Y20.27%
Revenue Next Year-6.95%
Revenue Next 2Y-1.93%
Revenue Next 3Y-0.15%
Revenue Next 5Y0.72%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
1COV.DE Yearly Revenue VS Estimates1COV.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5B 10B 15B
1COV.DE Yearly EPS VS Estimates1COV.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6 8

1

4. Valuation

4.1 Price/Earnings Ratio

1COV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 74.09, which means the current valuation is very expensive for 1COV.
Based on the Price/Forward Earnings ratio, 1COV is valued a bit more expensive than the industry average as 68.18% of the companies are valued more cheaply.
1COV is valuated expensively when we compare the Price/Forward Earnings ratio to 23.33, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 74.09
1COV.DE Price Earnings VS Forward Price Earnings1COV.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, 1COV is valued a bit more expensive than 66.67% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 16.26
1COV.DE Per share data1COV.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

1COV's earnings are expected to grow with 48.40% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y60.31%
EPS Next 3Y48.4%

0

5. Dividend

5.1 Amount

No dividends for 1COV!.
Industry RankSector Rank
Dividend Yield N/A

COVESTRO AG

FRA:1COV (10/23/2025, 7:00:00 PM)

59.96

-0.24 (-0.4%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)10-30 2025-10-30
Inst Owners25.07%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap11.33B
Revenue(TTM)13.84B
Net Income(TTM)-378000000
Analysts49.47
Price Target61.98 (3.37%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.01
Dividend Growth(5Y)-70.61%
DP-0.26%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-681.03%
Min EPS beat(2)-1222.75%
Max EPS beat(2)-139.31%
EPS beat(4)1
Avg EPS beat(4)-330.2%
Min EPS beat(4)-1222.75%
Max EPS beat(4)201.01%
EPS beat(8)1
Avg EPS beat(8)-4314.94%
EPS beat(12)2
Avg EPS beat(12)-2882.46%
EPS beat(16)4
Avg EPS beat(16)-2161.83%
Revenue beat(2)0
Avg Revenue beat(2)-5.71%
Min Revenue beat(2)-6.91%
Max Revenue beat(2)-4.5%
Revenue beat(4)0
Avg Revenue beat(4)-5.8%
Min Revenue beat(4)-6.91%
Max Revenue beat(4)-4.5%
Revenue beat(8)0
Avg Revenue beat(8)-4.99%
Revenue beat(12)1
Avg Revenue beat(12)-3.71%
Revenue beat(16)4
Avg Revenue beat(16)-2.08%
PT rev (1m)-0.16%
PT rev (3m)-1.51%
EPS NQ rev (1m)-18.93%
EPS NQ rev (3m)-218.18%
EPS NY rev (1m)-31.72%
EPS NY rev (3m)-577.27%
Revenue NQ rev (1m)-4.92%
Revenue NQ rev (3m)-11.02%
Revenue NY rev (1m)-2.77%
Revenue NY rev (3m)-8.89%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 74.09
P/S 0.82
P/FCF N/A
P/OCF 14.95
P/B 1.84
P/tB 2.26
EV/EBITDA 16.26
EPS(TTM)-2.01
EYN/A
EPS(NY)0.81
Fwd EY1.35%
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)4.01
OCFY6.69%
SpS73.2
BVpS32.56
TBVpS26.55
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.86%
ROE -6.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 14.09%
FCFM N/A
ROA(3y)-1.76%
ROA(5y)1.73%
ROE(3y)-3.61%
ROE(5y)3.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)1.42%
ROCE(5y)6.03%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-78.51%
OM growth 5Y-54.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18%
GM growth 5Y-7.1%
F-Score4
Asset Turnover1.05
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Debt/EBITDA 2.39
Cap/Depr 88.46%
Cap/Sales 6.32%
Interest Coverage N/A
Cash Conversion 85.65%
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 0.74
Altman-Z 2.35
F-Score4
WACC6.4%
ROIC/WACCN/A
Cap/Depr(3y)75.52%
Cap/Depr(5y)82.02%
Cap/Sales(3y)5.15%
Cap/Sales(5y)5.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.42%
EPS Next Y-7.01%
EPS Next 2Y60.31%
EPS Next 3Y48.4%
EPS Next 5Y20.27%
Revenue 1Y (TTM)-1.98%
Revenue growth 3Y-3.75%
Revenue growth 5Y2.7%
Sales Q2Q%-8.43%
Revenue Next Year-6.95%
Revenue Next 2Y-1.93%
Revenue Next 3Y-0.15%
Revenue Next 5Y0.72%
EBIT growth 1Y-183.74%
EBIT growth 3Y-79.32%
EBIT growth 5Y-52.83%
EBIT Next Year267.68%
EBIT Next 3Y84.36%
EBIT Next 5Y41.79%
FCF growth 1Y-126.73%
FCF growth 3Y-60.36%
FCF growth 5Y-28.37%
OCF growth 1Y-37.61%
OCF growth 3Y-26.52%
OCF growth 5Y-8.84%